, Volume 39, Issue 6, pp 2040–2044 | Cite as

Activated CD4+ and CD8+ T Cell Proportions in Multiple Sclerosis Patients

  • Borros Arneth


The goal of this study was to trace the course of multiple sclerosis (MS) by evaluating the lymphocyte subpopulation counts and the levels of CD4+ and CD8+ T cell activation using flow cytometry. Samples obtained from healthy subjects (N = 40) and patients with MS (N = 290) were analyzed. Lymphocytes were labeled for the surface markers CD4+, CD8+, CD3+, CD16+, CD19+, CD45+, and CD53+ and the activation marker HLA-DR+. Cell counts were then determined using flow cytometry. A high degree of inter-individual variability was observed in the counts of all lymphocyte subtypes in the MS group. A significantly lower proportion of CD3+ T cells (69 ± 14 % in healthy subjects and 60 ± 17 % as a percent of total lymphocytes in MS patients), CD4+ T cells (41 ± 11 and 28 ± 18 %, respectively), and a significantly higher proportion of NK T cells (12 ± 5 and 25 ± 21 %, respectively) were observed in patients with MS than in healthy subjects. These differences led to a lowered CD4+/CD8+ T cell ratio. Furthermore, a significantly lower proportion of activated CD4+ T cells (HLA-DR+ CD4+; from 48 ± 10 to 38 ± 15 % as a percent of CD4+ cells) was observed in patients with MS than in healthy subjects. The high level of inter-individual variability in lymphocyte cell counts and the counts of activated T cells suggest that MS is a complex and heterogeneous disease.


multiple sclerosis T lymphocytes CD4+ T helper cells CD8+ cytotoxic T cells 



The author thanks Prof. Ziemssen and the team at MS Center Dresden for providing clinical data and patient samples.

Compliance with Ethical Standards

This study was approved by the Institutional Review Board (IRB) of Dresden University and conformed to the directives of the Helsinki Declaration. All patients who were involved in this study provided written informed consent.

Competing Interests

The author declares that he has no competing interests.

Supplementary material

10753_2016_441_MOESM1_ESM.xls (77 kb)
ESM 1 (XLS 77 kb)


  1. 1.
    Harrer, A., G. Pilz, P. Wipfler, K. Oppermann, J. Sellner, W. Hitzel, E. Haschke-Becher, S. Afazel, T. Rispens, D. van der Kleij, E. Trinka, and J. Kraus. 2015. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. Clinical Experimental Immunology 180: 383–392.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rudnicka, J., M. Czerwiec, E. Grywalska, D. Siwicka-Gieroba, M. Walankiewicz, A. Grafka, M. Zgurski, A. Surdacka, H. Bartosik-Psujek, and J. Rolinski. 2015. Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients—preliminary study. Central European Journal of Immunology 40: 354–359.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Stüve, O., C.M. Marra, A. Bar-Or, M. Niino, P.D. Cravens, S. Cepok, E.M. Frohman, J.T. Phillips, G. Arendt, K.R. Jerome, L. Cook, F. Grand’Maison, B. Hemmer, N.L. Monson, and M.K. Racke. 2006. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Archives of Neurology 63: 1383–1387.CrossRefPubMedGoogle Scholar
  4. 4.
    Arneth, B. 2015. Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS. Journal of Translational Medicine 13: 341.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hernández-Hoyos, G., M. Anderson, C. Wang, E. Rothenberg, and J. Alberola-Ila. 2003. GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Immunity 19: 83–94.CrossRefPubMedGoogle Scholar
  6. 6.
    Egerton, M., R. Scollay, and K. Shortman. 1990. Kinetics of mature T-cell development in the thymus. Proceedings of the National academy of Sciences of the United States of America 87: 2579–2582.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Merkenschlager, M. 1997. How many thymocytes audition for selection? Journal Experimental Medicine 186: 1149–1158.CrossRefGoogle Scholar
  8. 8.
    Merkenschlager, M., C. Benoist, and D. Mathis. 1994. Evidence for a single-niche model ofpositive selection. Proceedings of the National academy of Sciences of the United States of America 91: 11694–11698.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sinclair, C., I. Bains, A. Yates, and B. Seddon. 2013. Asymmetric thymocyte death underlies the CD4:CD8 T-cell ratio in the adaptive immune system. Proceedings of the National academy of Sciences of the United States of America 110: E2905–E2914.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Schlub, T., J. Sun, S. Walton, S. Robbins, A. Pinto, M. Munks, et al. 2011. Comparing the kinetics of NK cells, CD4, and CD8 T cells in murine cytomegalovirus infection. Journal of Immunology 187: 1385–1392.CrossRefGoogle Scholar
  11. 11.
    Cohen, S.J., M. Hazebergh, D. Hamann, S. Otto, J. Borleffs, F. Miedema, et al. 2000. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. Journal of Acquired Immune Deficiency Syndromes 25: 203–211.CrossRefGoogle Scholar
  12. 12.
    Chiarini, M., A. Sottini, D. Bertoli, F. Serana, L. Caimi, S. Rasia, R. Capra, and L. Imberti. 2015. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients. Multiple Sclerosis 6: 726–734.CrossRefGoogle Scholar
  13. 13.
    Claes, N., T. Dhaeze, J. Fraussen, B. Broux, B. Van Wijmeersch, P. Stinissen, R. Hupperts, N. Hellings, and V. Somers. 2014. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PLoS One 9, e111115.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Salou, M., B. Nicol, A. Garcia, and D.A. Laplaud. 2015. Involvement of CD8(+) T cells in multiple sclerosis. Frontiers in Immunology 6: 604.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Henault, D., L. Galleguillos, C. Moore, T. Johnson, A. Bar-Or, and J. Antel. 2013. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Neurology 81: 1768–1772.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sinha, S., A.W. Boyden, F.R. Itani, M. Crawford, and N. Karandikar. 2015. CD8+ T-cells as immune regulators of multiple sclerosis. Frontiers in Immunology 6: 619.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fischer, H.J., J. Brandt, T. Lingner, F. Odoardi, A. Flügel, A. Weishaupt, and H. Reichardt. 2016. Modulation of CNS autoimmune responses by CD8+ T cells coincides with their oligoclonal expansion. Journal Neuroimmunology 290: 26–32.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Institute of Laboratory Medicine and Pathobiochemistry, Molecular DiagnosticsUniversity Hospital of Giessen and Marburg, Justus Liebig University GiessenGiessenGermany
  2. 2.Institute for Clinical Chemistry and Laboratory MedicineUniversity of Technology DresdenDresdenGermany

Personalised recommendations